Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 4Stomach Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1Solid Cancers 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Bevacizumab 187Fluorouracil 150Leucovorin 135Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43Nivolumab 43regorafenib 42Folfox protocol 39Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 23Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × onartuzumab × Clear all
NCT01418222 2017-05-30

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Genentech, Inc.

Phase 2 Completed
194 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡